Comparing new treatments for arthritis of the spine or joints
Part of Bones, joints & muscles, Skin clinical trials.
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with axial spondyloarthritis (a type of arthritis affecting the spine) or psoriatic arthritis (arthritis linked to psoriasis).
- You are 18 years old or older.
- You have just started (within the past month) a new treatment for your arthritis that is one of these medications: bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
- You are not currently taking part in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people recently diagnosed with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine). It tests whether a standardized global review and education program can help patients better understand and manage their condition.
This study looks at how people with psoriatic arthritis respond to different types of biologic or targeted synthetic drugs. Participants will be starting a new treatment, and the study will check both clinical symptoms and immune system changes over time.
This trial compares two newer medications for people with axial spondyloarthritis who have already tried a TNF inhibitor (a type of biologic) without success. The goal is to see which one works better at reducing symptoms like pain and stiffness.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
This study enrolls people who have recently been diagnosed with certain inflammatory conditions affecting the spine, joints, or the eye. Researchers are looking to better understand how these illnesses start and how they may be linked, which could help guide future care.
This trial tests an investigational drug for people with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine and pelvis). It also includes a group of healthy volunteers for comparison. The study aims to see if the drug is safe and effective.
Hear when a new Axial Spondylarthritis (axSpA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.